Intellectual Property - October 26, 2016
Dilaforette change name and announces IPO
Dilaforette Holding AB, a clinical-stage drug development and Karolinska Development portfolio company, announces its name change to Modus Therapeutics Holding AB and its intention to undertake an Initial Public Offering (IPO). A rights issue is planned in connection with the IPO in order to finance the further clinical development of the company’s lead candidate sevuparin for […]
Pharma Business - May 10, 2016
Karolinska Development’s first quarter 2016
Karolinska Development has published its Interim Report for the period January to March 2016. Significant events during Karolinska Development’s first quarter this year include Aprea raising SEK 437 million in a Series B financing round from a syndicate of specialist international life science investors. This was the largest ever completed by a Karolinska Development portfolio company and […]
Acquisition - February 16, 2016
Dilaforette signs agreement with Arabian Gulf University
Dilaforette, focused on treatments for patients with sickle-cell disease, and Arabian Gulf University, based in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC). Under the scope of the agreement, Dilaforette and AGU’s collaboration will […]
